bioRxiv Science⌕ Search

Biology subjects

Zemiti, S.

Publications and source records attributed to Zemiti, S..

2 recordsLinked to original sources

Metabolic rewiring of cancer cells induces metastasis via ERK5 but triggers recognition by NK cells

Metastasis is largely controlled by Natural Killer (NK) cell-mediated immune surveillance. To colonize new environments, cancer cells undergo epithelial to mesenchymal transition (EMT), which allows them to detach and migrate. EMT is fueled by fatty acid oxidation (FAO), which partially replaces glycolytic-based tumor metabolism. Whether metabolic rewiring affects the targeting of cancer cells by NK cells remains unknown. Here, we show that forcing solid cancer cells to perform FAO by inhibiting pyruvate dehydrogenase kinase 1 with dichloroacetate (DCA) activates extracellular signal-regulated kinase-5 (ERK5), triggering EMT and tumor cell migration and invasion. Concomitantly, FAO induces the expression of ligands that mediate NK cell recognition. Consequently, NK cells better infiltrated DCA-treated 3D tumor spheroids, where they exerted their cytotoxic effects. DCA-treated cells showed increased migration in a zebrafish model, whereas metastasis from mammary cancer cells grafted into immune-deficient mice was enhanced by DCA. These migrating/metastatic cells are preferentially killed by NK cells, which strongly limit their invasive potential. Hence, FAO promotes both metastasis and NK-mediated tumor surveillance, highlighting the Achilles heel of metastatic cells, which may offer new therapeutic opportunities. TeaserMetastasis recognition and killing by immune cells, such as NK cells, requires a metabolic shift that relies on lipid metabolism.

cancer biology↗

The SUMOylation inhibitor TAK-981 (Subasumstat) triggers IFN-I-dependent activation of Natural Killer cells against Acute Myeloid Leukemias.

Natural Killer (NK) cells play a pivotal role in mounting an anti-cancer immune response. Patients with diminished NK cells number and activity face less favorable prognosis. Promising therapeutic strategies include the adoptive transfer of NK cells or the reactivation of patients own NK cells. TAK-981, a first-in-class inhibitor of SUMOylation undergoing phase I/II clinical trials for cancer, is emerging as an immunomodulatory drug. Here, we demonstrate that TAK-981 activates NK cells from healthy donors and patients with Acute Myeloid Leukemia (AML), a cancer with very poor prognosis. TAK-981 heightens their degranulation capacity, secretion of inflammatory cytokines (IFN-{gamma}, TNF-, FasL), and cytotoxicity against AML cells. In vivo, TAK-981 also enhances the anti-leukemic activity of ex-vivo expanded human NK cells. At the molecular level, TAK-981 first induces IFNB1 gene in NK cells, leading to the secretion of type I Interferon (IFN-I), which binds to the Interferon receptor IFNAR. This induces Interferon-Stimulated Genes (ISG) and activates NK cells in vitro and in vivo. Finally, TAK-981 stimulates IFN-I secretion by monocytes, which contributes to the activation of NK cells in trans. Altogether, targeting SUMOylation could be a promising strategy to reactivate AML patients NK cells and enhance the efficiency of NK cells-based therapies. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=109 SRC="FIGDIR/small/580882v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@1a5fd47org.highwire.dtl.DTLVardef@974336org.highwire.dtl.DTLVardef@bdb99dorg.highwire.dtl.DTLVardef@1e4fe15_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗